Department of Health and Human Services' logo Department of Health and Human Services

Public Health Service
Food and Drug Administration
Southwest Region
Denver District Office

 

Bldg 20, Denver Federal Ctr
PO Box 25087
6th Ave & Kipling St
Denver, CO 80225-0087
Telephone: 303-236-3000
FAX: 303-236-3100

August 4, 1999
WARNING LETTER
VIA CERTIFIED MAIL, RETURN RECEIPT REQUESTED

David R Wimmer, PhD, President
Scientific Health Products, Inc.
d/b/a Natural Wonders
351 W 6160 S
Salt Lake City, UT 8412

Ref. No. DEN-99-17

Dear Dr Wimmer:

During an inspection of your firm conducted on March 12, 1999, Consumer Safety Officer Elvin R. Smith determined your firm manufactures a variety of oral and topical products. This letter is in reference to the promotion, marketing, and distribution of these products by your fh-m.

Claims are made for some of your products through labels and promotional literature, including catalogs:

Furthermore, the promotional literature "Natural Wonders Product Catalog" includes numerous disease claims in the form of testimonials. Examples of such claims include:

Based on the claims for these products and their intended uses, these products are drugs as defined by Section 201(g) of the Federal Food, Drug, and Cosmetic Act (the Act). They are also new drugs as defined by Section 201(p) of the Act and may not be legally marketed in the United States without approved New Drug Applications as found in Section 505 of the Act. These drugs are misbranded in that their labeling fails to bear adequate directions for use under Section 502(f)(1) of the Act. These products are further misbranded under Section 502(a) of the Act in that their labeling is false and misleading as it suggests that the products are safe and effective for their intended uses when this has not been established.

In addition, the following "Homeolixir" products are offered as homeopathic over-the-counter (OTC) drugs to treat or cure diseases which are neither self-limiting nor amenable to self diagnosis by the laity:

These "Homeolixir" products are misbranded as described in Sections 503(b)(1) and (b)(4) of the Act because they are not dispensed under the supervision of a practitioner licensed by law and the labels of the drugs fail to bear, at a minimum, the symbol "Rx only."

Furthermore, Section 201(ff)(2) of the Act provides that the term dietary supplement means, in part, an article intended for ingestion. The product "Aloe Wonder" (concentrated liquid Aloe Vera) is offered as a beverage and spray. Your catalog makes claims for benefits of these products when taken internally and/or externally. Since this product is represented for external (i.e., topical) use, it is excluded from the definition of a dietary supplement under Section 201(ff)(2) of the Act because it is not "intended for ingestion."

This letter is not intended to be an all inclusive review of all labeling and products your firm markets. It is your responsibility to ensure that all products marketed by your firm are in compliance with the Act and its implementing regulations.

We request that you take prompt action to correct these violations. Failure to promptly correct violations may result in enforcement action being initiated by the Food and Drug Administration without further notice. The Federal Food, Drug and Cosmetic Act provides for the seizure of illegal products and for injunction against the manufacturer and/or distributor of illegal products.

Please notify this office in writing, within 15 working days of your receipt of this letter, of the specific steps you have taken to correct the stated violations. You should also include an explanation of each step being taken to identify and make corrections to assure that similar violations will not recur. If corrective action cannot be completed. within 15 working days, please state the reason for the delay and the time within which the corrections will be implemented.

Your reply should be directed to Ms Shelly L. Maifarth, Compliance Officer, at the above letterhead address.

Sincerely,
/s/
Gary C. Dean
District Director

This page was posted on August 20, 2006.

Links to Recommended Companies